← Leaderboards
Nabil Thalji
University Of Pennsylvania
$101,130
Attributed
$101,130
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $42.2K · FY2013–15$50K$37.5K$25K$12.5K$0
'13
'14
'15
Funding mix
By agency
NIH$101,130 · 1
By mechanism
F30$101,130 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Susan Sheps Margulies$12,397,982
- Mark L Kahn$46,704,160
- Mortimer Poncz$48,626,684
- Kenneth J McLaughlin$1,801,345
- Holger Willenbring$13,377,791
Others in their field
Top investigators on “Adverse Effects”
- James Dennis Neaton · Northwestern University$203,539,316
- John M Lachin · George Washington University$139,991,329
- Elizabeth A Thom · George Washington University$126,101,581
- David M Nathan · Massachusetts Institute Of Technology$120,651,895
- Constance Ann Benson · University Of California, San Diego$114,806,215
- Wafaa M. El-Sadr · Columbia University Health Sciences$102,102,044
Research focus
Adverse EffectsActive SitesAnticoagulantsAnticoagulationAnimalsAntithrombin IiiAtrial FibrillationBaseBinding (Molecular Function)BiochemicalAntidotesBlood CoagulationBlood VesselsCoagulation ProcessCofactorCore ProteinDeep Vein ThrombosisDoseElementsEmergency SituationEnzyme PrecursorsEnzymesEventExcision
Grant awards (3)
Reversal of Direct FXa Inhibitors Using Zymogen-Like Variants of FXa$29,671
F30 · FY2015 · HL · contact PI
Reversal of Direct FXa Inhibitors Using Zymogen-Like Variants of FXa$29,227
F30 · FY2014 · HL · contact PI
Reversal of Direct FXa Inhibitors Using Zymogen-Like Variants of FXa$42,232
F30 · FY2013 · HL · contact PI